16. Net Loss Per Share
Basic loss per share is computed by dividing net loss attributable to common stockholders (numerator) by the weighted average number of common shares outstanding (denominator) during the period. For the three and nine-month periods ended September 30, 2021 and 2020, as the Company was in a net loss position, the diluted loss per share computations for such periods did not assume the conversion of the Convertible Notes, exercise of stock options or vesting of RSUs or PRSUs as they would have had an anti-dilutive effect on loss per share.
The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding for the three and nine-month periods ended September 30, 2021 and 2020, as the inclusion thereof would have been anti-dilutive:
Three Months Ended September 30,
Nine Months Ended September 30,
Shares issuable upon conversion of Convertible Notes
Unvested restricted stock units
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!
Other recent filings from the company include the following:
Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022
Departure of Directors or Certain - Jan. 10, 2022
SVP of Intercept Pharmaceuticals just disposed of 2,455 shares - Jan. 4, 2022
SVP of Intercept Pharmaceuticals just disposed of 542 shares - Jan. 4, 2022
Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 1,712 shares - Jan. 4, 2022